The Peptidings Evidence Framework

This is how Peptidings decides what to say about a compound—and how honestly to say it. Every article on this site is built on the same framework: a five-tier evidence hierarchy, a four-category verdict system, a Claims versus Evidence audit, and an editorial voice that does not round up. Understanding the framework is the shortest path to reading the site well.

Most peptide content online is either promotional (selling you something) or defensive (refusing to say anything concrete). Peptidings exists between those extremes. The framework is the scaffolding that makes it possible to write substantively about compounds whose evidence quality ranges from tens of thousands of patients in Phase III trials to a single injection in a single rabbit in 1977—without pretending the two are equivalent, and without giving up on either.

1. The Five Evidence Tiers

Every compound covered on Peptidings is assigned an evidence tier. The tier reflects the strongest available human evidence for that compound—not community enthusiasm, not mechanistic plausibility, and not what the compound is marketed as. The tier is the scientific floor, not the ceiling.

Approved Drug
FDA-approved (or international-equivalent) for a specified indication. Replicated Phase III trials. Known safety profile in thousands of patients.

Clinical Trials
Registered Phase I or Phase II trials in humans. Early efficacy signals, emerging safety data. Not approved. Not over the finish line.

Pilot / Limited Human Data
Small uncontrolled human studies, case series, single-site trials, or non-Western clinical traditions without Western replication.

Preclinical Only
Animal models, cell culture, or in silico work. No controlled human trials for the discussed endpoint. The compound has never been proven to do in a human what it does in a rodent.

It’s Complicated
Reserved for compounds where a single tier would mislead—evidence is strong for one indication, absent for another, or entangled with regulatory ambiguity.

Tier assignments are not a ranking of importance or interest. A Tier 4 compound can be scientifically fascinating and worth a long article. A Tier 1 compound can still have open questions about off-label use. The tier tells you what kind of evidence exists, not whether the compound matters.

The full tier definitions, examples, and current classifications for every compound on the site live on the Peptide Evidence Levels page.

2. The Four Verdict Categories

The evidence tier is mechanical. The verdict is editorial. Every compound article opens with a BLUF card—Bottom Line Up Front—that assigns one of four verdict categories. The verdict factors the evidence tier alongside safety profile, cost, availability, regulatory status, and what we call the evidence-to-hype ratio: how wide is the gap between what the community claims and what the data actually shows?

The verdict and the tier are not the same thing, and they do not always move together. A Tier 4 compound with an understood mechanism and a clean safety signal can be a Reasonable Bet. A Tier 3 compound with red-flag adverse events or aggressive marketing can be Thin Ice. Reading the tier and the verdict together tells you more than either in isolation.

Strong Foundation
FDA-approved or regulatory-equivalent. Controlled trial evidence replicated across multiple studies. The evidence supports the use.

Reasonable Bet
Understood mechanism, plausible safety, coherent rationale. Not proven—but the scientific case is real and the downside is bounded.

Eyes Open
Interesting mechanism, significant gaps. The compound may be legitimate, but you proceed knowing what you don’t know.

Thin Ice
Evidence-to-hype ratio severely unfavorable. The community is well ahead of the science. Safety concerns, regulatory red flags, or both.

Verdicts are editorial judgments. They are not prescriptions. Peptidings does not tell readers what to take. The verdict is the site’s honest read on the evidence-to-risk math—what a careful reader would want to know before spending hours on a 7,000-word article.

3. Claims versus Evidence

Every compound article contains a Claims versus Evidence table. The left column lists claims commonly made about the compound—in marketing copy, biohacker forums, peptide subreddits, and Telegram channels. The right column states what the published evidence actually shows. The verdict column connects the two.

This is the most direct way the site does its job. If a community claim is supported by human trials, the table says so. If the claim rests on a single rodent study, the table says that too. If the claim is contradicted by the evidence, the table says that most clearly of all. The point is not to debunk—the point is to locate each claim on the actual evidence map.

Ryan, the fitness coach who stakes his professional authority on what he says to clients, reads the Claims versus Evidence table first. So does Dr. Priya, the physician whose patients are asking her about peptides. If you want the fastest version of any compound article, skip to the Claims table.

4. The Dutch Uncle Voice

Peptidings speaks in what the editorial team calls the Dutch Uncle voice. The Dutch Uncle is the trusted, knowledgeable friend who respects you enough to be honest. The Dutch Uncle does not hedge. The Dutch Uncle does not flatter. The Dutch Uncle does not moralize. The Dutch Uncle tells you what the data says, names the gaps, and trusts you to reach your own conclusion.

Concretely, that means:

Precision over vagueness. “In rodent models”—not “studies show.” “A Phase II trial in 40 patients”—not “clinical research suggests.” When we know the size of the study, we say the size of the study.
Attribution over assertion. Every claim points to where it comes from. Community reporting is labeled as community reporting. Animal data is labeled as animal data. Human trials are labeled by phase, size, and endpoint.
Gaps named explicitly. If a compound has never been tested in a single human for the indication being discussed, the article says so—and keeps saying so until the evidence changes.
No false reassurance. “Generally well tolerated in short-term studies” is not the same as “safe.” The framework refuses the shortcut.
No false alarm. Where concerns are speculative, the article calls them speculative. Where risks are documented, the article documents them.

The Dutch Uncle voice is not harsh and is not cold. It is the voice of someone who cares enough about the reader to refuse to round up.

5. The Plain English Layer

Every article is written for two readers at once: the physician or pharmacologist who wants the mechanism in clinical terms, and the smart, self-directed person who is not a specialist. The framework resolves that tension with Plain English callouts. After any dense pharmacological passage, a green callout box translates the core idea in one or two sentences of ordinary language.

Plain English

Most of the biology can be explained without jargon if someone is willing to do the translation work. Peptidings does that work on every article.

The test the editorial team applies: if a reader reads only the Plain English callouts in an article, can they reconstruct the core argument? If yes, the callouts are doing their job. If no, they get rewritten until they do.

6. The Three-Tier Reading Gradient

The opening sequence of every compound article is deliberately tiered by reading level—verified against Flesch-Kincaid scoring during editorial review:

BLUF card: eighth-grade reading level or lower. Worth it or not, in three to five sentences, with no jargon. This is the section written for the reader who needs an answer in thirty seconds.
Intro summary: roughly eleventh-grade reading level. Technical terms are permitted. This is the bridge for a reader who is deciding whether to commit to the full article.
Article body: twelfth grade and above. The full Dutch Uncle scientific voice. Full terminology. This is where the real work of the article happens.

The gradient is a smooth staircase, not a cliff. Each step down in reading level still honors the evidence. The BLUF card does not simplify by overstating certainty. It simplifies by choosing the right words.

7. What the Framework Will Not Do

The evidence framework is defined as much by what it refuses as by what it permits.

It will not make recommendations. Peptidings reports what the evidence shows. It does not tell readers what to take, how much to take, or when to take it. The verdict categories are editorial assessments of evidence quality, not prescriptions.
It will not treat preclinical data as clinical data. A mechanism that works in a mouse may or may not work in a human. The framework insists on naming that gap every time, no matter how elegant the mechanism.
It will not inflate weak evidence. A single positive study generates a hypothesis, not an established fact. A case series is not a trial. A community report is not evidence of efficacy.
It will not be “balanced” where the evidence is not balanced. If eight well-conducted trials show an effect and one poorly-designed trial does not, the framework will say the effect is supported—not that the science is “divided.”
It will not pretend community protocols are validated. Where Peptidings reports doses from self-experimentation communities, those sections are labeled as anthropological reporting, not endorsement.

8. How to Read Peptidings

A practical reading order for any compound article:

Read the BLUF card. Tier, verdict, three-to-five-sentence summary. If you need an answer in thirty seconds, this is it.
Scan the Quick Facts table. Regulatory status, WADA status, evidence tier, structural class, clusters the compound belongs to.
Read the Claims versus Evidence table. This is where the claims you have probably heard from other sources get compared to the actual data.
Jump to the Human Evidence Landscape section. This section explicitly names what has been studied in humans—and what has not.
Read Safety, Risks, and Limitations. Never skip this section.
Then, if you want the full picture, read the mechanism and research sections. That is where the article earns its length.

9. What If the Framework Is Wrong?

Evidence is a moving target. A Tier 4 compound can become Tier 3 the week a new pilot study publishes. A Reasonable Bet can become Eyes Open when a safety signal emerges. A Thin Ice verdict can be updated if a well-designed trial reverses the evidence-to-hype math.

Every article carries a review date. Articles are revisited on a rolling basis. When the framework gets a compound wrong—when a study publishes that meaningfully changes the picture—the article gets updated, the verdict gets revisited, and the change is noted. This is what editorial honesty actually looks like: not pretending to have been right, but updating when the evidence moves.

Readers who spot errors, new citations the team missed, or framing that has aged poorly are invited to reach out via the contact page. Good corrections make the site better.